EGFR and non-small cell lung carcinoma: In non-small-cell lung cancer, EGFR mutation and/or amplification have been reported as possible predictive factors of sensitivity to EGFR tyrosine kinase inhibitors (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004; Cappuzzo et al, 2005).